Improvements in survival and clinical benefit with gemcitabine as first- line therapy for patients with advanced pancreas cancer: A randomized trial

Howard A. Burris, Malcolm J. Moore, John Andersen, Mark R. Green, Mace L. Rothenberg, Manuel R. Modiano, M. Christine Cripps, Russell K. Portenoy, Anna Maria Storniolo, Peter Tarassoff, Robert Nelson, F. Andrew Dorr, C. D. Stephens, Daniel D. Von Hoff

Research output: Contribution to journalArticle

4370 Citations (Scopus)

Abstract

Purpose: Most patients with advanced pancreas cancer experience pain and must limit their daily activities because of tumor-related symptoms. To date, no treatment has had a significant impact on the disease. In early studies with gemcitabine, patients with pancreas cancer experienced an improvement in disease-related symptoms. Based on those findings, a definitive trial was performed to assess the effectiveness of gemcitabine in patients with newly diagnosed advanced pancreas cancer. Patients and Methods: One hundred twenty- six patients with advanced symptomatic pancreas cancer completed a lead-in period to characterize and stabilize pain and were randomized to receive either gemcitabine 1,000 mg/m2 weekly x 7 followed by 1 week of rest, then weekly x 3 every 4 weeks thereafter (63 patients), or to fluorouracil (5-FU) 600 mg/m2 once weekly (63 patients). The primary efficacy measure was clinical benefit response, which was a composite of measurements of pain (analgesic consumption and pain intensity), Karnofsky performance status, and weight. Clinical benefit required a sustained (≤ 4 weeks) improvement in at least one parameter without worsening in any others. Other measures of efficacy included response rate, time to progressive disease, and survival. Results: Clinical benefit response was experienced by 23.8% of gemcitabine- treated patients compared with 4.8% of 5-FU-treated patients (P = .0022). The median survival durations were 5.65 and 4.41 months for gemcitabine-treated and 5-FU-treated patients, respectively (P = .0025). The survival rate at 12 months was 18% for gemcitabine patients and 2% for 5-FU patients. Treatment was well tolerated. Conclusion: This study demonstrates that gemcitabine is more effective than 5-FU in alleviation of some disease-related symptoms in patients with advanced, symptomatic pancreas cancer. Gemcitabine also confers a modest survival advantage over treatment with 5-FU.

Original languageEnglish (US)
Pages (from-to)2403-2413
Number of pages11
JournalJournal of Clinical Oncology
Volume15
Issue number6
StatePublished - Jun 1997
Externally publishedYes

Fingerprint

gemcitabine
Pancreatic Neoplasms
Survival
Fluorouracil
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., ... Von Hoff, D. D. (1997). Improvements in survival and clinical benefit with gemcitabine as first- line therapy for patients with advanced pancreas cancer: A randomized trial. Journal of Clinical Oncology, 15(6), 2403-2413.

Improvements in survival and clinical benefit with gemcitabine as first- line therapy for patients with advanced pancreas cancer : A randomized trial. / Burris, Howard A.; Moore, Malcolm J.; Andersen, John; Green, Mark R.; Rothenberg, Mace L.; Modiano, Manuel R.; Cripps, M. Christine; Portenoy, Russell K.; Storniolo, Anna Maria; Tarassoff, Peter; Nelson, Robert; Dorr, F. Andrew; Stephens, C. D.; Von Hoff, Daniel D.

In: Journal of Clinical Oncology, Vol. 15, No. 6, 06.1997, p. 2403-2413.

Research output: Contribution to journalArticle

Burris, HA, Moore, MJ, Andersen, J, Green, MR, Rothenberg, ML, Modiano, MR, Cripps, MC, Portenoy, RK, Storniolo, AM, Tarassoff, P, Nelson, R, Dorr, FA, Stephens, CD & Von Hoff, DD 1997, 'Improvements in survival and clinical benefit with gemcitabine as first- line therapy for patients with advanced pancreas cancer: A randomized trial', Journal of Clinical Oncology, vol. 15, no. 6, pp. 2403-2413.
Burris, Howard A. ; Moore, Malcolm J. ; Andersen, John ; Green, Mark R. ; Rothenberg, Mace L. ; Modiano, Manuel R. ; Cripps, M. Christine ; Portenoy, Russell K. ; Storniolo, Anna Maria ; Tarassoff, Peter ; Nelson, Robert ; Dorr, F. Andrew ; Stephens, C. D. ; Von Hoff, Daniel D. / Improvements in survival and clinical benefit with gemcitabine as first- line therapy for patients with advanced pancreas cancer : A randomized trial. In: Journal of Clinical Oncology. 1997 ; Vol. 15, No. 6. pp. 2403-2413.
@article{7bf97fca70b14aa29534860297e7951a,
title = "Improvements in survival and clinical benefit with gemcitabine as first- line therapy for patients with advanced pancreas cancer: A randomized trial",
abstract = "Purpose: Most patients with advanced pancreas cancer experience pain and must limit their daily activities because of tumor-related symptoms. To date, no treatment has had a significant impact on the disease. In early studies with gemcitabine, patients with pancreas cancer experienced an improvement in disease-related symptoms. Based on those findings, a definitive trial was performed to assess the effectiveness of gemcitabine in patients with newly diagnosed advanced pancreas cancer. Patients and Methods: One hundred twenty- six patients with advanced symptomatic pancreas cancer completed a lead-in period to characterize and stabilize pain and were randomized to receive either gemcitabine 1,000 mg/m2 weekly x 7 followed by 1 week of rest, then weekly x 3 every 4 weeks thereafter (63 patients), or to fluorouracil (5-FU) 600 mg/m2 once weekly (63 patients). The primary efficacy measure was clinical benefit response, which was a composite of measurements of pain (analgesic consumption and pain intensity), Karnofsky performance status, and weight. Clinical benefit required a sustained (≤ 4 weeks) improvement in at least one parameter without worsening in any others. Other measures of efficacy included response rate, time to progressive disease, and survival. Results: Clinical benefit response was experienced by 23.8{\%} of gemcitabine- treated patients compared with 4.8{\%} of 5-FU-treated patients (P = .0022). The median survival durations were 5.65 and 4.41 months for gemcitabine-treated and 5-FU-treated patients, respectively (P = .0025). The survival rate at 12 months was 18{\%} for gemcitabine patients and 2{\%} for 5-FU patients. Treatment was well tolerated. Conclusion: This study demonstrates that gemcitabine is more effective than 5-FU in alleviation of some disease-related symptoms in patients with advanced, symptomatic pancreas cancer. Gemcitabine also confers a modest survival advantage over treatment with 5-FU.",
author = "Burris, {Howard A.} and Moore, {Malcolm J.} and John Andersen and Green, {Mark R.} and Rothenberg, {Mace L.} and Modiano, {Manuel R.} and Cripps, {M. Christine} and Portenoy, {Russell K.} and Storniolo, {Anna Maria} and Peter Tarassoff and Robert Nelson and Dorr, {F. Andrew} and Stephens, {C. D.} and {Von Hoff}, {Daniel D.}",
year = "1997",
month = "6",
language = "English (US)",
volume = "15",
pages = "2403--2413",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Improvements in survival and clinical benefit with gemcitabine as first- line therapy for patients with advanced pancreas cancer

T2 - A randomized trial

AU - Burris, Howard A.

AU - Moore, Malcolm J.

AU - Andersen, John

AU - Green, Mark R.

AU - Rothenberg, Mace L.

AU - Modiano, Manuel R.

AU - Cripps, M. Christine

AU - Portenoy, Russell K.

AU - Storniolo, Anna Maria

AU - Tarassoff, Peter

AU - Nelson, Robert

AU - Dorr, F. Andrew

AU - Stephens, C. D.

AU - Von Hoff, Daniel D.

PY - 1997/6

Y1 - 1997/6

N2 - Purpose: Most patients with advanced pancreas cancer experience pain and must limit their daily activities because of tumor-related symptoms. To date, no treatment has had a significant impact on the disease. In early studies with gemcitabine, patients with pancreas cancer experienced an improvement in disease-related symptoms. Based on those findings, a definitive trial was performed to assess the effectiveness of gemcitabine in patients with newly diagnosed advanced pancreas cancer. Patients and Methods: One hundred twenty- six patients with advanced symptomatic pancreas cancer completed a lead-in period to characterize and stabilize pain and were randomized to receive either gemcitabine 1,000 mg/m2 weekly x 7 followed by 1 week of rest, then weekly x 3 every 4 weeks thereafter (63 patients), or to fluorouracil (5-FU) 600 mg/m2 once weekly (63 patients). The primary efficacy measure was clinical benefit response, which was a composite of measurements of pain (analgesic consumption and pain intensity), Karnofsky performance status, and weight. Clinical benefit required a sustained (≤ 4 weeks) improvement in at least one parameter without worsening in any others. Other measures of efficacy included response rate, time to progressive disease, and survival. Results: Clinical benefit response was experienced by 23.8% of gemcitabine- treated patients compared with 4.8% of 5-FU-treated patients (P = .0022). The median survival durations were 5.65 and 4.41 months for gemcitabine-treated and 5-FU-treated patients, respectively (P = .0025). The survival rate at 12 months was 18% for gemcitabine patients and 2% for 5-FU patients. Treatment was well tolerated. Conclusion: This study demonstrates that gemcitabine is more effective than 5-FU in alleviation of some disease-related symptoms in patients with advanced, symptomatic pancreas cancer. Gemcitabine also confers a modest survival advantage over treatment with 5-FU.

AB - Purpose: Most patients with advanced pancreas cancer experience pain and must limit their daily activities because of tumor-related symptoms. To date, no treatment has had a significant impact on the disease. In early studies with gemcitabine, patients with pancreas cancer experienced an improvement in disease-related symptoms. Based on those findings, a definitive trial was performed to assess the effectiveness of gemcitabine in patients with newly diagnosed advanced pancreas cancer. Patients and Methods: One hundred twenty- six patients with advanced symptomatic pancreas cancer completed a lead-in period to characterize and stabilize pain and were randomized to receive either gemcitabine 1,000 mg/m2 weekly x 7 followed by 1 week of rest, then weekly x 3 every 4 weeks thereafter (63 patients), or to fluorouracil (5-FU) 600 mg/m2 once weekly (63 patients). The primary efficacy measure was clinical benefit response, which was a composite of measurements of pain (analgesic consumption and pain intensity), Karnofsky performance status, and weight. Clinical benefit required a sustained (≤ 4 weeks) improvement in at least one parameter without worsening in any others. Other measures of efficacy included response rate, time to progressive disease, and survival. Results: Clinical benefit response was experienced by 23.8% of gemcitabine- treated patients compared with 4.8% of 5-FU-treated patients (P = .0022). The median survival durations were 5.65 and 4.41 months for gemcitabine-treated and 5-FU-treated patients, respectively (P = .0025). The survival rate at 12 months was 18% for gemcitabine patients and 2% for 5-FU patients. Treatment was well tolerated. Conclusion: This study demonstrates that gemcitabine is more effective than 5-FU in alleviation of some disease-related symptoms in patients with advanced, symptomatic pancreas cancer. Gemcitabine also confers a modest survival advantage over treatment with 5-FU.

UR - http://www.scopus.com/inward/record.url?scp=8244254377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8244254377&partnerID=8YFLogxK

M3 - Article

C2 - 9196156

AN - SCOPUS:8244254377

VL - 15

SP - 2403

EP - 2413

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -